ethyl 7-hydroxy-5-methyl-thieno[3,2-b]pyridine-6-carboxylate | 223141-69-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: ethyl 7-hydroxy-5-methyl-thieno[3,2-b]pyridine-6-carboxylate
• 英文别名: ethyl 5-methyl-7-oxo-4H-thieno[3,2-b]pyridine-6-carboxylate
• CAS: 223141-69-3；96516-53-9
• 化学式: C₁₁H₁₁NO₃S
• 分子量: 237.279
• InChiKey: KNFYWEPPBFJHHC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  83.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 7-hydroxy-5-methyl-thieno[3,2-b]pyridine-6-carboxylate 在 三氯氧磷 作用下， 反应 2.0h， 生成 ethyl 7-Chloro-5-methyl-thieno[3,2-b]pyridine-6-carboxylate
  参考文献：
  名称：

  Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors

  摘要：

  式1的化合物在由TNF-α介导的疾病条件中很有用，如类风湿关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和软骨退行性损失。

  公开号：

  US20030208066A1
• 作为产物：
  描述：

  ethyl 3-[(2-methoxycarbonyl-3-thienyl)amino]crotonate 在 sodium ethanolate 、 盐酸 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 ethyl 7-hydroxy-5-methyl-thieno[3,2-b]pyridine-6-carboxylate
  参考文献：
  名称：

  Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors

  摘要：

  式1的化合物在由TNF-α介导的疾病条件中很有用，如类风湿关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和软骨退行性损失。

  公开号：

  US20030208066A1

文献信息

• Acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
  申请人：Wyeth Holdings Corporation

  公开号：EP1279674A3

  公开（公告）日：2003-10-01

  Compounds of the formula are provided wherein P and Q are provided that when P is Q is and vice versa; which are useful in disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  提供了公式为的化合物，其中P和Q是，要求当P是Q时，Q也是P；这些化合物在由TNF-α介导的疾病条件中非常有用，例如类风湿关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和软骨退行性损失。
• Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
  申请人：American Cyanamid Company

  公开号：US06228869B1

  公开（公告）日：2001-05-08

  This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula: B wherein B is P and Q are provided that when P is Q is and vice versa; or a pharmaceutically acceptable salt thereof.

  这项发明提供了一种低分子量、非肽类的基质金属蛋白酶和TNF-α转化酶（TACE，肿瘤坏死因子-α转化酶）的抑制剂，其化学式为：B其中B是P和Q，当P为时，Q为，反之亦然；或其药用盐。
• Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
  申请人：——

  公开号：US20010046989A1

  公开（公告）日：2001-11-29

  This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula: B wherein B is 1 2 T, U, W, and X are each, independently, carbon or nitrogen, provided that when T or U is carbon, either may be optionally substituted with R 1 ; Y is carbon, nitrogen, oxygen or sulfur, provided that at least one of T, U, W, X, and Y is not carbon, and further provided that no more than 2 of T, U, W, and X are nitrogen; 3 is a phenyl ring or is a heteroaryl ring of ring 5-6 atoms which may contain 0-2 heteratoms selected from nitrogen, oxygen, and sulfur, in addition to any heteroatoms defined by W or X; wherein the phenyl or heteroaryl ring may be optionally mono-, di-, or tri- substituted with R 1 ; Z is a phenyl, naphthyl, heteroaryl, or heteroaryl fused to phenyl, wherein the heteroaryl moiety contains of 5-6 ring atoms and 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur; wherein the phenyl, naphthyl, heteroaryl, or phenyl fused heteroaryl moieties may be optionally mono-, di-, or tri- substituted with R 1 ; R 1 is hydrogen, halogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cyclocalkyl of 3-6 carbon atoms, —(CH 2 ) n Z, —OR 2 , —CN, —COR 2 , perfluoroalkyl of 1-4 carbon atoms, —CONR 2 R 3 , —S(O) x R 2 —OPO(OR 2 )OR 3 , —PO(OR 2 )R 3 , —OC(O)NR 2 R 3 , —COOR 2 , —CONR 2 R 3 , —SO 3 H, —NR 2 R 3 , —NR 2 COR 3 , —NR 2 COOR 3 , —SO 2 NR 2 R 3 , —NO 2 , —N(R 2 )SO 2 R 3 , —NR 2 CONR 2 R 3 , —NR 2 C(═NR 3 )NR 2 R 3 , —SO 2 NHCOR 4 , —CONHSO 2 R 4 , -tetrazol-5-yl, —SO 2 NHCN, —SO 2 NHCONR 2 R 3 or Z; V is a saturated or partially unsaturated heterocycloalkyl ring of 5-7 ring atoms having 1-3 heteroatoms selected from N, O, or S, which may be optionally mono-, or di-substituted with R 2 ; R 2 and R 3 are each, independently, hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R 4 is alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R 5 is hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, Z, or V; n=1-6; x=0-2 or a pharmaceutically acceptable salt thereof.

  这项发明提供了低分子量、非肽类的基质金属蛋白酶和TNF-α转化酶（TACE，肿瘤坏死因子-α转化酶）的抑制剂，其化学式为：其中 B 是 12T，U，W 和 X 分别独立地为碳或氮，但当 T 或 U 为碳时，可以选择性地用 R1 取代；Y 为碳、氮、氧或硫，要求 T、U、W、X 和 Y 中至少有一个不是碳，并且进一步要求 T、U、W 和 X 中不超过 2 个是氮；3 为苯环或是由 5-6 个原子组成的杂环，其中可能含有 0-2 个氮、氧或硫等杂原子，除了 W 或 X 定义的杂原子之外；苯或杂环可能选择性地单取代、双取代或三取代的 R1；Z 为苯、萘、杂环或与苯融合的杂环，其中杂环部分含有 5-6 个环原子和 1-3 个氮、氧或硫等杂原子；苯、萘、杂环或苯融合杂环部分可能选择性地单取代、双取代或三取代的 R1；R1 为氢、卤素、1-8 个碳原子的烷基、2-6 个碳原子的烯基、2-6 个碳原子的炔基、3-6 个碳原子的环烷基、—(CH2)nZ、—OR2、—CN、—COR2、1-4 个碳原子的全氟烷基、—CONR2R3、—S(O)xR2—OPO(OR2)OR3、—PO(OR2)R3、—OC(O)NR2R3、—COOR2、—CONR2R3、—SO3H、—NR2R3、—NR2COR3、—NR2COOR3、—SO2NR2R3、—NO2、—N(R2)SO2R3、—NR2CONR2R3、—NR2C(═NR3)NR2R3、—SO2NHCOR4、—CONHSO2R4、-四唑-5-基、—SO2NHCN、—SO2NHCONR2R3 或 Z；V 为由 5-7 个环原子组成、含有 1-3 个氮、氧或硫等杂原子的饱和或部分不饱和杂环烷基，可能选择性地单取代或双取代的 R2；R2 和 R3 分别独立地为氢、1-8 个碳原子的烷基、2-6 个碳原子的烯基、2-6 个碳原子的炔基、3-6 个碳原子的环烷基、1-4 个碳原子的全氟烷基、Z 或 V；R4 为1-8 个碳原子的烷基、2-6 个碳原子的烯基、2-6 个碳原子的炔基、3-6 个碳原子的环烷基、1-4 个碳原子的全氟烷基、Z 或 V；R5 为氢、1-8 个碳原子的烷基、2-6 个碳原子的烯基、2-6 个碳原子的炔基、Z 或 V；n=1-6；x=0-2 或其药用盐。
• Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
  申请人：——

  公开号：US20010025047A1

  公开（公告）日：2001-09-27

  This invention provides, low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF-&agr; converting enzyme (TACE, tumor necrosis factor-&agr; converting enzyme) of formula: B wherein B is 1 P and Q are 2 provided that when P is 3 and vice versa; T, U, W, and X are each, independently, carbon or nitrogen, provided that when T or U is carbon, either may be optionally substituted with R 1 ; Y is carbon, nitrogen, oxygen or sulfur, provided that at least one of T, U, W, X, and Y is not carbon, and further provided that no more than 2 of T, U, W, and X are nitrogen; 4 is a phenyl ring or is a heteroaryl ring of ring 5-6 atoms which may contain 0-2 heteratoms selected from nitrogen, oxygen, and sulfur, in addition to any heteroatoms defined by W or X; wherein the phenyl or heteroaryl ring may be optionally mono-, di-, or tri-substituted with R 1 ; Z is a phenyl, naphthyl, heteroaryl, or heteroaryl fused to phenyl, wherein the heteroaryl moiety contains of 5-6 ring atoms and 1-3 heteroatoms selected from nitrogen, oxygen, or sulfur; wherein the phenyl, naphthyl, heteroaryl, or phenyl fused heteroaryl moieties may be optionally mono-, di-, or tri-substituted with R 1 ; R 1 is hydrogen, halogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cyclocalkyl of 3-6 carbon atoms, —(CH 2 ) n Z, —OR 2 , —CN, —COR 2 , perfluoroalkyl of 1-4 carbon atoms, —CONR 2 R 3 , —S(O) X R 2 —OPO(OR 2 )OR 3 , —PO(OR 2 )R 3 , —OC(O)NR 2 R 3 , —COOR 2 , —CONR 2 R 3 , —SO 3 H, —NR 2 R 3 , —NR 2 COR 3 , —NR 2 COOR 3 , —SO 2 NR 2 R 3 , —NO 2 , —N(R 2 )SO 2 R 3 , —NR 2 CONR 2 R 3 ,—NR 2 C(═NR 3 )NR 2 R 3 , —SO 2 NHCOR 4 , —CONHSO 2 R 4 , -tetrazol-5-yl, —SO 2 NHCN, —SO 2 NHCONR 2 R 3 , or Z; V is a saturated or partially unsaturated heterocycloalkyl ring of 5-7 ring atoms having 1-3 heteroatoms selected from N, O, or S, which may be optionally mono-, or di-substituted with R 2 ; R 2 and R 3 are each, independently, hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R 4 is alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R 5 is hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, Z, or V; n=1-6; X=0-2 or a pharmaceutically acceptable salt thereof.

  该发明提供了低分子量、非肽类的基质金属蛋白酶和TNF-α转化酶（TACE，肿瘤坏死因子-α转化酶）抑制剂，其化学式为：B其中，B为1。P和Q为2，但当P为3时，反之亦然；T、U、W和X各自独立地为碳或氮，但当T或U为碳时，可以任选一个用R1取代；Y为碳、氮、氧或硫，但至少有一个T、U、W、X和Y不为碳，并且进一步提供不超过2个T、U、W和X为氮；4为苯环或环5-6原子的杂环环，除了由W或X定义的任何杂原子外，还可以包含0-2个从氮、氧和硫中选择的杂原子，其中苯环或杂环环可以选择性地单取代、二取代或三取代R1；Z为苯、萘、杂环或与苯融合的杂环，其中杂环基团包含5-6个环原子和1-3个从氮、氧或硫中选择的杂原子；其中苯、萘、杂环或苯融合的杂环基团可以选择性地单取代、二取代或三取代R1；R1为氢、卤素、1-8个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、3-6个碳原子的环烷基、-(CH2)nZ、-OR2、-CN、-COR2、1-4个碳原子的全氟烷基、-CONR2R3、-S(O)XR2-OPO(OR2)OR3、-PO(OR2)R3、-OC(O)NR2R3、-COOR2、-CONR2R3、-SO3H、-NR2R3、-NR2COR3、-NR2COOR3、-SO2NR2R3、-NO2、-N(R2)SO2R3、-NR2CONR2R3、-NR2C(═NR3)NR2R3、-SO2NHCOR4、-CONHSO2R4、-四唑-5-基、-SO2NHCN、-SO2NHCONR2R3或Z；V为5-7个环原子的饱和或部分不饱和的杂环烷基环，其中有1-3个从N、O或S中选择的杂原子，可以选择性地单取代或二取代R2；R2和R3各自独立地为氢、1-8个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、3-6个碳原子的环烷基、1-4个碳原子的全氟烷基、Z或V；R4为1-8个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、3-6个碳原子的环烷基、1-4个碳原子的全氟烷基、Z或V；R5为氢、1-8个碳原子的烷基、2-6个碳原子的烯基、2-6个碳原子的炔基、Z或V；n为1-6；X为0-2或其药学上可接受的盐。
• ACETYLENIC ORTHO-SULFONAMIDO AND PHOSPHINIC ACID AMIDO BICYCLIC HETEROARYL HYDROXAMIC ACIDS AS TACE INHIBITORS
  申请人：American Cyanamid Company

  公开号：EP1157024B1

  公开（公告）日：2002-11-06